Highlights Alligator Bioscience AB

Equities

ATORX

SE0000767188

Market Closed - Nasdaq Stockholm Other stock markets 11:29:49 2024-04-29 am EDT			5-day change	1st Jan Change
0.925 ^SEK	0.00%		-6.94%	+34.25%

Apr. 26	Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	CI
Apr. 05	Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	Apr. 26	CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	Mar. 26	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	Mar. 07	CI
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 08	CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation	Feb. 08	CI
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	Jan. 29	CI
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab	23-10-12	CI
Alligator Bioscience Obtains Orphan Status for Pancreatic Cancer Therapy in EU	23-08-21	MT
Alligator Bioscience Advances Research Partnership With Orion	23-07-31	MT
Alligator Bioscience AB Announces Technical Feasibility in the Second Program Under the Research Collaboration and License Agreement with Orion Corporation	23-07-31	CI
Alligator Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-13	CI
Alligator Bioscience AB Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist	23-06-30	CI
Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	23-06-26	CI
Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023	23-06-05	CI
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in First Quarter 2024	23-04-12	CI
Alligator Bioscience Announces FDA Authorization to Initiate Mitazalimab OPTIMIZE-2 Phase 2 Trial in Urothelial Carcinoma	23-04-03	CI
Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer	23-03-14	CI
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial	23-02-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alligator Bioscience AB

Equities

ATORX

SE0000767188

Highlights

Filters